{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:54:05Z","timestamp":1791982445057,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.xphs.2026.104523","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:28:58Z","timestamp":1791318538000},"page":"104523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["When pharmaceutical process data become manufacturing evidence: Evidence maturity and decision suitability"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8018-524X","authenticated-orcid":false,"given":"Yoseok","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104523_bib0001","series-title":"ICH Q10: Pharmaceutical Quality System","year":"2008"},{"key":"10.1016\/j.xphs.2026.104523_bib0002","series-title":"ICH Q8(R2): Pharmaceutical Development","year":"2009"},{"key":"10.1016\/j.xphs.2026.104523_bib0003","series-title":"ICH Q9(R1): Quality Risk Management. Step 4, Adopted 2023; Minor Correction January 15","year":"2025"},{"key":"10.1016\/j.xphs.2026.104523_bib0004","series-title":"PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance","year":"2004"},{"key":"10.1016\/j.xphs.2026.104523_bib0005","series-title":"Process Validation: General Principles and Practices","year":"2011"},{"key":"10.1016\/j.xphs.2026.104523_bib0006","series-title":"ICH Q13: Continuous Manufacturing of Drug Substances and Drug Products","year":"2022"},{"key":"10.1016\/j.xphs.2026.104523_bib0007","series-title":"Data Integrity and Compliance with Drug CGMP: Questions and Answers","year":"2018"},{"key":"10.1016\/j.xphs.2026.104523_bib0008","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cherd.2018.03.017","article-title":"Robust state estimation of feeding-blending systems in continuous pharmaceutical manufacturing","volume":"134","author":"Liu","year":"2018","journal-title":"Chem Eng Res Des"},{"issue":"3","key":"10.1016\/j.xphs.2026.104523_bib0009","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0967-0661(95)00014-L","article-title":"Statistical process control of multivariate processes","volume":"3","author":"MacGregor","year":"1995","journal-title":"Control Eng Pract"},{"key":"10.1016\/j.xphs.2026.104523_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-7439(95)80036-9","article-title":"Process analysis, monitoring and diagnosis, using multivariate projection methods","volume":"28","author":"Kourti","year":"1995","journal-title":"Chemom Intell Lab Syst"},{"key":"10.1016\/j.xphs.2026.104523_bib0011","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.compchemeng.2019.03.001","article-title":"A perspective on quality-by-control (QbC) in pharmaceutical continuous manufacturing","volume":"125","author":"Su","year":"2019","journal-title":"Comput Chem Eng"},{"key":"10.1016\/j.xphs.2026.104523_bib0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12247-017-9297-6","article-title":"A systematic framework for process control design and risk analysis in continuous pharmaceutical solid-dosage manufacturing","volume":"12","author":"Su","year":"2017","journal-title":"J Pharm Innov"},{"key":"10.1016\/j.xphs.2026.104523_bib0013","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.compchemeng.2014.02.029","article-title":"A systematic framework for onsite design and implementation of a control system in a continuous tablet manufacturing process","volume":"66","author":"Singh","year":"2014","journal-title":"Comput Chem Eng"},{"key":"10.1016\/j.xphs.2026.104523_bib0014","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104523_bib0015","series-title":"Development and Submission of Near Infrared Analytical Procedures","year":"2021"},{"key":"10.1016\/j.xphs.2026.104523_bib0016","series-title":"'GXP' Data Integrity Guidance and Definitions. Revision 1","year":"2018"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104523_bib0017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2018.01.003","article-title":"Process analytical technology in continuous manufacturing of a commercial pharmaceutical product","volume":"538","author":"Vargas","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104523_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jpba.2018.09.016","article-title":"Process analytical technology for continuous manufacturing tableting processing: a case study","volume":"162","author":"Pauli","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104523_bib0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijpharm.2017.07.041","article-title":"In-line Raman spectroscopic monitoring and feedback control of a continuous twin-screw pharmaceutical powder blending and tableting process","volume":"530","author":"Nagy","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104523_bib0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12247-015-9238-1","article-title":"Using residence time distributions (RTDs) to address the traceability of raw materials in continuous pharmaceutical manufacturing","volume":"11","author":"Engisch","year":"2016","journal-title":"J Pharm Innov"},{"key":"10.1016\/j.xphs.2026.104523_bib0021","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1016\/j.xphs.2017.06.015","article-title":"Regulatory Perspectives on continuous pharmaceutical Manufacturing: moving from theory to practice: September 26-27, 2016, International Symposium on the continuous manufacturing of pharmaceuticals","volume":"106","author":"Nasr","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104523_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122336","article-title":"Digital twin of a continuous direct compression line for drug product and process design using a hybrid flowsheet modelling approach","volume":"628","author":"Moreno-Benito","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104523_bib0023","series-title":"Artificial Intelligence in Drug Manufacturing","year":"2023"},{"key":"10.1016\/j.xphs.2026.104523_bib0024","series-title":"Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products","year":"2025"},{"key":"10.1016\/j.xphs.2026.104523_bib0025","series-title":"Guiding Principles of Good AI Practice in Drug Development","year":"2026"},{"key":"10.1016\/j.xphs.2026.104523_bib0026","series-title":"Industry 5.0: Towards a Sustainable, Human-Centric and Resilient European Industry","author":"Breque","year":"2021"},{"key":"10.1016\/j.xphs.2026.104523_bib0027","series-title":"ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management","year":"2019"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:32:19Z","timestamp":1791981139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0022354926003734"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104523","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When pharmaceutical process data become manufacturing evidence: Evidence maturity and decision suitability","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104523"}}